Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports

Clinical application of immune checkpoint inhibitors (CPIs) including nivolumab is expanding in the field of oncology treatment. Nivolumab is an anti-programmed death 1 protein (PD-1) antibody designed to augment an immunologic reaction against cancer cells. On the contrary, CPIs are known to cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryuzaki, Masaki, Tokuyama, Hirobumi, Uchiyama, Kiyotaka, Nakaya, Hideaki, Hasegawa, Kazuhiro, Miyashita, Kazutoshi, Konishi, Kohnosuke, Hashiguchi, Akinori, Wakino, Shu, Itoh, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566467/
https://www.ncbi.nlm.nih.gov/pubmed/31223235
http://dx.doi.org/10.1177/1179547619853647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566467/
https://www.ncbi.nlm.nih.gov/pubmed/31223235
http://dx.doi.org/10.1177/1179547619853647

Ejemplares similares